Lucid Diagnostics

Canaccord Genuity Acted as the Sole Placement Agent to Lucid Diagnostics Inc. on its $15.3 Million Registered Direct Offering

Canaccord Genuity is pleased to announce that on March 5, 2025, it completed a registered direct offering for Lucid Diagnostics Inc. (NASDAQ: LUCD) (the “Company”). The offering comprised of 13,939,331 shares of common stock at a purchase price of $1.10 per share, resulting in gross proceeds of $15.3 million. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Canaccord Genuity acted as the sole placement agent for the offering.
    
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM). The Company is focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. The Company’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.